Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Melanoma Research Alliance commits strategic research funding to improve the understanding about the causes of melanoma and to develop better treatments for this deadly disease.
“Our goal is to have perfect prediction to match patients to appropriate therapy,” said researcher Janis Taube, MD.
“You really have to be the CEO of your own health,” said melanoma survivor and patient advocate T. J. Sharpe.
SPORE grants have become the cornerstone of NCI’s efforts to advance collaborative, interdisciplinary translational cancer research.
Ken has lived with and in the shadow of melanoma since 1995, but he isn’t your typical patient and he hasn’t been cured of melanoma.
Can new therapies benefit patients with early stage melanoma, where spread of disease has yet to be observed?
“There were so many things that were outside of my control, so I decided to focus on the things that I could do something about.”
For patients, the decision to move forward with adjuvant therapy isn’t as cut and dry as it may seem.
New research asks if an alternative dosing schedule can produce the same effects with fewer side effects.
Melanoma researchers have several experimental animal models from which to choose, each with its own advantages and disadvantages.
The panel and the audience candidly discussed lifelong prevention concerns, fear of recurrence, feelings of isolation and survivor’s guilt.
Together, these trials indicate that triple combos show promise and while there are significant toxicities, they are mostly manageable.
Acquired resistance has sent many researchers back to the lab in an effort to uncover its cause, and new tools that may help to overcome it.
Given the limited data available, Mohs surgery is still not routinely performed for invasive melanoma of the skin.
The results of the study are huge and challenge the standard of care.
Investigators also shared progress made and challenges encountered when harnessing new technology to further their research goals.
Researchers are using multiple strategies to tackle the same problem—how to activate T cells in people who don’t respond to immunotherapy.
His work as a mentor and a sharer of ideas would prepare Chris Eyrich for his new mission as a melanoma advocate.
Join the Melanoma Research Alliance and share your message with the newly launched With Love, Me program.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.